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Background: Fish oil-derived long-chain omega-3 (n-3) polyunsaturated fatty acids (PUFAs), including eicosapentaenoic
acid (EPA) and docosahexaenoic acid (DHA), reduce plasma triglyceride (TG) levels. Genetic factors such as
single-nucleotide polymorphisms (SNPs) found in genes involved in metabolic pathways of n-3 PUFA could be
responsible for well-recognized heterogeneity in plasma TG response to n-3 PUFA supplementation. Previous
studies have shown that genes in the glycerophospholipid metabolism such as phospholipase A2 (PLA2) group
II, IV, and VI, demonstrate changes in their expression levels in peripheral blood mononuclear cells (PBMCs) after
n-3 PUFA supplementation.
Methods: A total of 208 subjects consumed 3 g/day of n-3 PUFA for 6 weeks. Plasma lipids were measured before and
after the supplementation period. Five SNPs in PLA2G2A, six in PLA2G2C, eight in PLA2G2D, six in PLA2G2F, 22 in PLA2G4A,
five in PLA2G6, and nine in PLA2G7 were genotyped. The MIXED Procedure for repeated measures adjusted for age, sex,
BMI, and energy intake was used in order to test whether the genotype, supplementation or interaction (genotype by
supplementation) were associated with plasma TG levels.
Results: The n-3 PUFA supplementation had an independent effect on plasma TG levels. Genotype effects on
plasma TG levels were observed for rs2301475 in PLA2G2C, rs818571 in PLA2G2F, and rs1569480 in PLA2G4A.
Genotype x supplementation interaction effects on plasma TG levels were observed for rs1805018 in PLA2G7
as well as for rs10752979, rs10737277, rs7540602, and rs3820185 in PLA2G4A.
Conclusion: These results suggest that, SNPs in PLA2 genes may influence plasma TG levels during a
supplementation with n-3 PUFA. This trial was registered at clinicaltrials.gov as NCT01343342.
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Cardiovascular disease (CVD) is the leading cause of mor-
tality worldwide [1]. Triglyceride (TG) is an independent
risk factor of CVD [2]. Fish oil-derived long-chain omega-
3 (n-3) polyunsaturated fatty acids (PUFAs), including
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unless otherwise stated.(DHA) play a significant role in preventing CVD [3]. The
potential underlying mechanisms of n-3 PUFAs for redu-
cing CVD risk are related to their hypo-triglyceridemic,
anti-inflammatory, anti-atherogenic, and anti-arrhytmic ef-
fects [4]. Health organizations around the world currently
recommend consumption of EPA and DHA to reduce
CVD risk [5-8]. More specifically, The American Heart As-
sociation recommends an intake of 2 to 4 g of EPA/DHA
per day for patients who need to lower their TG levels [5].
Yet, there is a well-recognized heterogeneity in the
plasma TG response to n-3 PUFA supplementation [9].al . This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Tremblay et al. Lipids in Health and Disease  (2015) 14:12 Page 2 of 9For example, in the Fish Oil Intervention and Genotype
(FINGEN) Study, 31% of all volunteers showed no re-
duction in plasma TG after taking 1.8 g EPA and DHA
per day for 8 weeks [10]. The inter-individual variability
observed in the plasma lipid response to an n-3 PUFA
supplementation may partly result from genetic varia-
tions in genes involved in metabolic pathways of n-3
PUFA [9,11,12]. Understanding the genetic determinants
of inter-individual variability to n-3 PUFA supplementa-
tion would provide a more rational basis for advising indi-
viduals on intake levels likely to achieve optimal reduction
in CVD risk [9].
Our team worked on differences in metabolomic and
transcriptomic profiles between responders and non-
responders to an n-3 PUFA supplementation and found
that the lipid metabolism pathways appears to be one
of the most different between those two groups [13].
Genes in the glycerophospholipid metabolism such as
phospholipase A2 (PLA2) group II, IV, and VI had
changes in their expression levels after n-3 PUFA sup-
plementation [13].
The PLA2 represents an important superfamily of en-
zymes that catalyze the hydrolysis of the ester bond at the
sn-2 position of phospholipids to yield non-esterified fatty
acids such as AA and lysophospholipids [14]. Usually, these
products lead to the generation of a variety of downstream
signaling molecules including prostaglandins, leukotrienes,
lysophospholipids, platelet activating factor (PAF), and oxi-
dized lipids [15-20]. AA release by PLA2 catalytic reaction
is the initial and rate-limiting step for the biosynthesis of
eicosanoids [21]. Currently these enzymes are classified
into six major groups with many subgroups, depending on
their functions and cellular locations: the secreted PLA2
(sPLA2), lipoprotein-associated PLA2 (Lp-PLA2), cytosolic
PLA2 calcium-dependent (cPLA2), cytosolic PLA2 calcium-
independent (iPLA2), lysosomal PLA2 (lPLA2) and adipose-
specific PLA2 (adPLA) [21]. In addition, elevated plasma
PLA2 activity, likely sPLA2G2A, is an independent risk fac-
tor for CVD [22,23] and variations on the PLA2G4A gene
are associated with a CVD phenotype mediated by dietary
PUFAs [24].
The objective of the present study is to examine whether
genetic variations in PLA2 genes influence plasma TG




A total of 254 subjects from the greater Quebec City
metropolitan area were recruited to participate in the study
between September 2009 and December 2011 via electronic
messages sent to university students and employees as well
as advertisements in local newspapers. The participants had
to be between 18 and 50 years old, have a body mass index(BMI) between 25 and 40 kg/m2, be non-smokers, and with
no current lipid-lowering medications. They also needed to
be free of any thyroid or metabolic disorders requiring
treatment, e.g. diabetes, hypertension, severe dyslipidemia,
and coronary heart disease (CHD). Subjects were not in-
cluded if they had taken n-3 PUFA supplements for at least
6 months prior to the beginning of the study. A total of 210
subjects completed the intervention protocol and 208 had
plasma TG levels data available for further analyses.
The experimental protocol was approved by the Ethics
Committees of Laval University Hospital Research Center
and Laval University. The trial was registered at clinical-
trials.gov as NCT01343342.
Study design and diets
First, subjects followed a two-week run-in period during
which they received dietary instructions by a trained regis-
tered dietitian to achieve the recommendations from
Canada’s Food Guide to Healthy Eating. They were asked
to apply these dietary recommendations and maintain
their body weight stable throughout the protocol. The
following instructions were given to ensure stable n-3
PUFA dietary intake: do not exceed two fish or seafood
servings per week (maximum 150 g), prefer white flesh
fish to fatty fish (examples were given), and avoid
enriched n-3 PUFA food such as milk, juices, bread,
and eggs. In addition, subjects were not allowed to take
n-3 PUFA supplementation (such as flaxseed), vitamins,
or natural health products during the protocol. They
were also asked to limit their alcohol consumption to
two drinks per week.
Second, after the two-week run-in period, subjects re-
ceived a bottle containing needed n-3 PUFA capsules
(Ocean Nutrition, Nova Scotia, Canada) for the following
six weeks of supplementation. Subjects had to take five cap-
sules per day (1 g of fish oil concentrate each) providing a
total of 3 g of n-3 PUFA (including 1.9 g EPA and 1.1 g
DHA) per day. Compliance was assessed from the return of
bottles and by measuring the incorporation of EPA and
DHA in plasma phospholipids (PL). The participants were
asked to report any deviation during the protocol, write
down their alcohol and fish consumption as well as the side
effects of supplementation. Before each phase, subjects re-
ceived detailed written and oral instructions on their diet.
A registered dietitian showed the participants how to
complete a 3-day (2 weekdays and 1 weekend day) food
journal before and after n-3 PUFA supplementation. Nutri-
tion Data System for Research software version 2011 (Nutri-
tion Coordinating Center (NCC), University of Minnesota,
Minneapolis, MN, USA) was used to analyse dietary intakes.
Anthropometric measurements
Body weight, height, and waist girth were measured ac-
cording to the procedures recommended by the Airlie
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as well as before and after n-3 PUFA supplementation.
BMI was calculated as weight in kilograms divided by
height in meters squared (kg/m2).
Biochemical parameters
Blood samples were collected from an antecubital vein
into vacutainer tubes containing EDTA after 12-hour
overnight fast and 48-hour alcohol abstinence. Blood
samples were drawn before the run-in period to identify
and exclude participants with metabolic disorders. After-
wards, the selected participants had blood samples taken
before and after the n-3 PUFA supplementation period.
Plasma was separated by centrifugation (2,500 g for
10 min at 4°C), and samples were aliquoted and frozen
for subsequent analyses. Plasma total cholesterol (TC) and
TG concentrations were measured using enzymatic assays
[26]. The high-density lipoprotein cholesterol (HDL-C)
fraction was obtained after precipitation of very-low dens-
ity lipoprotein (VLDL) and low-density lipoprotein (LDL)
particles in the infranatant with heparin manganese chlor-
ide [27]. LDL cholesterol (LDL-C) was calculated with the
Friedewald formula [28]. Apolipoprotein B-100 concentra-
tions were measured in plasma by the rocket immune-
electrophoretic method of Laurell, as previously described
[29]. Plasma C-reactive protein (CRP) was measured by
nephelometry (Prospec equipment Behring) using a sensi-
tive assay [30].
Fatty acid composition of plasma phospholipids
According to a modified Folch method, plasma lipids were
extracted with chloroform:methanol (2:1, by volume) [31].
Total PL were separated by thin layer chromatography using
a combination of acetic acid and isopropyl ether. Fatty acids
of isolated PL were then methylated and capillary gas chro-
matography was then used to obtain fatty acids profiles. This
technique has been previously validated [32].
SNP Selection and genotyping
SNPs in PLA2G2A, PLA2G2C, PLA2G2D, PLA2G2F,
PLA2G4A, PLA2G6, and PLA2G7 were identified with the
International HapMap Project SNP database, based on the
National Center for Biotechnology Information (NCBI)
B36 assembly Data Rel phase II + III, build 126 (Table 1).
Tagger procedure in Haploview software V4.2 was used to
determine tag SNPs (tSNPs) using a minor allele frequency
(MAF) of 5% and pairwise tagging (R2 ≥ 0.80). The LD pro-
cedure in Haploview V4.2 was then used to examine linkage
disequilibrium (LD) between 5 SNPs in PLA2G2A, 6 in
PLA2G2C, 8 in PLA2G2D, 6 in PLA2G2F, 22 in PLA2G4A,
5 in PLA2G6, and 9 in PLA2G7 covering all common varia-
tions (MAF > 5%) in these genes. Most of the SNPs
were in LD (R2 ≥ 0.80), and the mean R2 was 0.943 for
PLA2G2A, 0.974 for PLA2G2C, 1.0 for PLA2G2D,0.976 for PLA2G2F, 0.975 for PLA2G4A, 0.968 for
PLA2G6, and 0.973 for PLA2G7. The SIGMA GenElute
Gel Extraction Kit (Sigma-Aldrich Co., St. Louis, MO,
USA) has been used to extract genomics DNA. Selected
SNPs (Table 1) were genotyped using validated primers and
TaqMan probes (Thermo Fisher Scientific, Waltham, MA,
USA) [33]. DNA was then mixed with TaqMan Universal
PCR Master Mix (Thermo Fisher Scientific.), with a gene-
specific primer and probe mixture (predeveloped TaqMan
SNP Genotyping Assays; Thermo Fisher Scientific.) in a final
volume of 10 μL. Thereafter, genotypes were determined
using a 7500 Real-Time PCR System and analyzed using
ABI Prism SDS version 2.0.5 (Thermo Fisher Scientific.).
Minor allele homozygotes with a genotype frequency <5%
were grouped with heterozygotes for statistical analyses.
Statistical analyses
All statistical analyses were performed with SAS Statistical
Software V9.3 (SAS Institute, Cary, N.C., USA), except for
the ALLELE Procedure, which was done with SAS Genetics
V9.3. The ALLELE Procedure was used to verify departure
from the Hardy-Weinberg equilibrium (HWE) and calcu-
late MAF. Values that were not normally distributed were
log10 or negative reciprocal transformed before analysis.
ANOVA was used to test for significant differences in
metabolic characteristics between men and women at base-
line with age, sex, and BMI included in the model. A paired
t-test was used to test for significant differences between
various nutrient intakes before and after n-3 PUFA supple-
mentation. A linear regression using the stepwise bidirec-
tional elimination approach was applied to assess which
SNPs could explain part of the plasma TG level variance.
The 61 SNPs were in HWE. First, the MIXED procedure
for repeated measures was used to test for the effects of the
genotype, supplementation and genotype × supplementa-
tion interaction on plasma TG in a model adjusted for age,
sex, BMI, and energy intake. Secondly, ANOVAs adjusted
for age, sex, BMI, energy intake, and pre-supplementation
plasma TG levels were used to test the differences in TG
levels after supplementation between genotypic groups.
Statistical significance was defined as p ≤ 0.05.
Results
Allele frequencies of selected SNPs are shown in
Table 1. All SNPs were in HWE. Therefore, associa-
tions with 61 SNPs were tested in statistical analyses.
The percent coverage was 90% for PLA2G2A, 85% for
PLA2G2C, 90% for PLA2G2D, 80% for PLA2G2F, 85%
for PLA2G4A, 98% for PLA2G6, and 93% for PLA2G7.
While most of the SNPs selected were intronic, one
PLA2G2C SNP, one PLA2G2D SNP, and two PLA2G7 SNPs
were located in exons and resulted in amino acid changes:
rs6426616 (Gln→Arg), rs584367 (Ser→Gly), rs1805017
(Arg→His), and rs1805018 (Ile→Thr).
Table 1 Selected polymorphisms in phospholipase A2 genes
Gene dbSNP No. Sequence Position Allele frequency
PLA2G2A rs876018 ATAC[A/T]TGAT 3-UTR A (n = 352) 0.8421 T (n = 66) 0.1579
rs955587 GCGT[A/G]GACT Intron G (n = 352) 0.8381 A (n = 68) 0.1619
rs3753827 GTAA[G/T]GCCC Intron G (n = 233) 0.5574 T (n = 185) 0.4426
rs11573156 GGAG[C/G]AGCT 5-UTR C (n = 326) 0.7762 G (n = 94) 0.2238
rs11573142 ATGG[C/T]ATTC NearGene-5 T (n = 406) 0.9667 C (n = 14) 0.0333
PLA2G2C rs6426616 AGCC[A/G]GCCC Missense Q [Gln]- > R [Arg] G (n = 249) 0.5929 A (n = 171) 0.4071
rs12139100 GGGG[C/T]GAAG Stop-gain C (n = 356) 0.8476 T (n = 64) 0.1524
rs10916716 ACCC[A/G]GGCC Intron A (n = 358) 0.8524 G (n = 62) 0.1476
rs2301475 GGAG[A/G]TATT Intron A (n = 294) 0.7000 G (n = 98) 0.3000
rs10916712 GAAG[G/C]TGTG 3-UTR C (n = 322) 0.76677 G (n = 98) 0.2333
rs10916718 GCTC[A/G]AAGC Intron A (n = 237) 0.5643 G (n = 183) 0.4357
PLA2G2D rs578459 TATC[A/T]TCCA 3-UTR A (n = 234) 0.5571 T (n = 186) 0.4429
rs16823482 ATTT[T/C]TCAC Intron T (n = 399) 0.9500 C (n = 21) 0.0500
rs3736979 ACTG[G/A]GTGC Intron G (n = 309) 0.7357 A (n = 111) 0.2643
rs584367 GTGC[A/G]GCAT Missense S [Ser] - > G [Gly] G (n = 262) 0.6238 A (n = 158) 0.3762
rs12045689 GGAG[T/C]AAGA Intron T (n = 381) 0.9071 C (n = 39) 0.0929
rs679667 CCCC[G/A]CTGC Intron G (n = 381) 0.9071 A (n = 39) 0.0929
rs17354769 AACT[A/G]GGGC NearGene-5 A (n = 399) 0.9545 G (n = 19) 0.0455
rs10916711 CTAG[T/C]GATT Intron T (n = 266) 0.6425 C (n = 148) 0.3575
PLA2G2F rs12065685 GGGC[C/T]TCTG Non-coding exon T (n = 369) 0.8786 C (n = 51) 0.1214
rs6657574 TGAC[C/T]TTGC Non-coding exon C (n = 345) 0.8214 T (n = 75) 0.1786
rs11582551 ATCT[C/T]CTGT Intron T (n = 303) 0.7214 C (n = 117) 0.2786
rs818571 CGCC[C/T]GGAC 3-UTR C (n = 296) 0.7048 T (n = 124) 0.2952
rs631134 ATTC[G/A]GTGA NearGene-5 G (n = 335) 0.7976 A (n = 85) 0.2024
rs11583904 TGAG[A/G]TGGA Intron A (n = 71) 0.169 G (n = 349) 0.831
PLA2G4A rs979924 TACA[C/T]TGCA NearGene-5 C (n = 33) 0.0786 T (n = 387) 0.9214
rs2076075 ATTC[G/A]TATAC Intron G (n = 381) 0.9071 A (n = 39) 0.0929
rs3736741 TTCC[A/G]GGCT Intron A (n = 320) 0.7619 G (n = 100) 0.2381
rs10911949 CTAA[C/T]GGCA Intron C (n = 222) 0.5286 T (n = 198) 0.4714
rs10752979 TCTC[A/G]TTGT Intron A (n = 68) 0.1619 G (n = 352) 0.8381
rs1160719 TTTC[A/G]TTAT Intron A (n = 79) 0.1881 G (n = 341) 0.8119
rs10737277 ATCA[C/G]ACAC Intron C (n = 231) 0.55 G (n = 189) 0.45
rs12720702 AATA[A/G]CAAG Intron A (n = 386) 0.919 G (n = 34) 0.081
rs7522213 ATTA[C/T]ATCC Intron C (n = 403) 0.9595 T (n = 17) 0.0405
rs7540602 CTCT[G/T]GACA Intron G (n = 379) 0.9024 T (n = 41) 0.0976
rs10157410 TTTT[C/G]ACTA Intron C (n = 57) 0.1357 G (n = 363) 0.8643
rs12720497 CCAG[C/T]GACC Intron C (n = 262) 0.6238 T (n = 158) 0.3762
rs4651331 CAAG[G/T]AGCA Intron G (n = 101) 0.2405 T (n = 319) 0.7595
rs1569480 TCAC[A/G]ATGG Intron A (n = 236) 0.5619 G (n = 184) 0.4381
rs10911935 ACTC[G/T]TGAT Intron G (n = 337) 0.8024 T (n = 83) 0.1976
rs12353944 AAAA[C/T]CTGA Intron C (n = 76) 0.181 T (n = 344) 0.819
rs11576330 CACA[C/T]CCAC Intron C (n = 38) 0.0905 T (n = 382) 0.9095
rs10489410 TTTC[G/T]TAGT Intron G (n = 16) 0.0381 T (n = 404) 0.9619
rs10911946 TTAG[C/T]TGAC Intron C (n = 299) 0.7119 T (n = 121) 0.2881
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Table 1 Selected polymorphisms in phospholipase A2 genes (Continued)
rs3820185 CATG[G/T]TGAG Intron G (n = 283) 0.3262 T (n = 137) 0.3262
rs12746200 CCAG[A/G]ATCA Intron A (n = 384) 0.9143 G (n = 36) 0.0857
rs11587539 TAGG[A/T]TTTG Intron A (n = 243) 0.5786 T (n = 177) 0.4214
PLA2G6 rs5750546 TAAA[G/A]GAAA Intron G (n = 259) 0.6167 A (n = 161) 0.3833
rs132989 GGGG[G/A]ACAG Intron G (n = 392) 0.9333 A (n = 28) 0.0677
rs133016 AGTG[G/A]ACCC Intron G (n = 215) 0.5119 A (n = 205) 0.4881
rs2235346 TGCC[C/A]GGGG Intron C (n = 200) 0.4762 A (n = 220) 0.5238
rs2284060 AATC[A/G]ACGC Intron A (n = 228) 0.5429 G (n = 192) 0.4571
PLA2G7 rs12195701 ATGT[G/A]GATC Intron G (n = 333) 0.7929 A (n = 87) 0.2071
rs12528807 CCAC[A/C]GATC Intron A (n = 379) 0.9024 C (n = 41) 0.0976
rs1421368 ATGA[C/T]CTTA Intron C (n = 34) 0.081 T (386) 0.919
rs1421378 TGAT[T/C]CGGA NearGene-5 T (n = 244) 0.581 C (n = 176) 0.419
rs17288905 TCCA[T/C]AGCA Intron T (n = 378) 0.9214 C (n = 33) 0.0786
rs1805017 GATC[G/A]CCTT Missense R [Arg] - > H [His] G (n = 304) 0.7238 A (n = 116) 0.2762
rs1805018 GAAA[T/C]AGGG Missense I [Ile] - > T [Thr] T (n = 403) 0.9595 C (n = 17) 0.0405
rs6929105 TGAA[A/G]GATG Intron A (n = 98) 0.2333 G (n = 322) 0.7667
rs7756935 GGGG[G/T]TAGA Intron G (n = 85) 0.2024 T (n = 335) 0.7976
Allelic frequencies were obtained using the ALLELE Procedure (SAS Genetics v9.3).
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presented in Table 2. As required by inclusion criteria,
men and women were overweight (mean BMI > kg/m2)
and had mean plasma TG levels slightly above the cut-
off value of 1.13 mmol/l recommended by the American
Heart Association (AHA) for optimal plasma TG levels
[34]. Significant gender differences were observed for
weight, HDL-C, TG, and CRP levels. Daily energy and
nutrient intakes measured by a 3-day food record areTable 2 Baseline characteristics of the study sample (n = 208)
Characteristics All Men Women pa
Study population, n 208 96 112
Age, years 30.8 ± 8.7 31.2 ± 8.1 30.5 ± 9.1 0.55
Weight, kgb,d 81.4 ± 13.9 87.2 ± 13.4 76.4 ± 12.3 <0.0001*
BMIb,d 27.8 ± 3.7 27.5 ± 3.6 28.2 ± 3.8 0.13
Waist circumference, cm 93.3 ± 10.8 94.8 ± 11.0 92.0 ± 10.4 0.06
TC, mmol/Le 4.82 ± 1.01 4.80 ± 1.00 4.83 ± 1.02 0.75
HDL-C, mmol/Le 1.46 ± 0.39 1.29 ± 0.31 1.61 ± 0.39 <0.0001*
LDL-C, mmol/Le 2.79 ± 0.87 2.91 ± 0.87 2.70 ± 0.86 0.08
TG, mmol/Lb,e 1.23 ± 0.64 1.32 ± 0.74 1.15 ± 0.53 0.04*
Apolipoprotein B, g/le 0.86 ± 0.25 0.89 ± 0.25 0.84 ± 0.25 0.12
CRP, mg/Lc,e 3.13 ± 7.10 1.66 ± 2.45 4.39 ± 9.24 0.02*
Values are means ± SD. *p < 0.05.
ap value from ANOVA for the differences between men and women
at baseline;
bvalues are log10 transformed;
cvalues are negative reciprocal transformed;
dvalues adjusted for age;
evalues adjusted for age and BMI.presented in Table 3. After n-3 supplementation, energy,
carbohydrate, protein, and saturated fat intakes including
n-3 supplements were significantly different from the pre-
supplementation period (p = 0.006, p < 0.0001, p = 0.002,
and p < 0.0001 respectively). PUFA intakes after the sup-
plementation (including fish oil capsules and food) were
significantly higher (p = 0.0002).
Subjects were asked to limit their fish intake to no more
than two servings per week (one serving of fish = 75 g).
Based on the compliance questionnaire, the mean intake
of fish was of 0.89 serving per week during the n-3 PUFA
supplementation period. Accordingly, subjects who had
consumed the maximum quantity of fish permitted each
week (150 g) would have had an extra 0.43 g of EPA and
DHA per day. Following the supplementation, TG levels
decreased in 71.2% and increased in 28.8% of the subjects
(delta mean ± SD = −0.25 ± 0.15 and 0.20 ± 0.19 mmol/l,
respectively), as previously reported [35].
We further tested the independent effect of the genotype,
the supplementation or the interaction (genotype by supple-
mentation) on plasma TG levels. First, the supplementation
had an independent effect on plasma TG levels (p < 0.0001),
as expected. Secondly, three SNPS, one of PLA2G2C
(rs2301475), one of PLA2G2F (rs818571), and one of
PLA2G4A (rs1569480) were associated with plasma TG
levels. Thirdly, interaction effects between n-3 PUFA sup-
plementation and genotype were observed for one SNP of
PLA2G7 (rs1805018) and four of PLA2G4A (rs10752979,
rs10737277, rs7540602, and rs3820185) (Table 4). All as-
sociations remained significant after further adjustments
Table 3 Nutrient intakes before and after n-3 PUFA supplementation (n = 208)
Dietary Intakes Pre-supplementation Post-supplementation P-values*
(including n-3 PUFA supplements)
Energy (kcal) 2273 ± 590 2186 ± 566 0.006
Carbohydrate (g/d) 286.7 ± 78.9 263.4 ± 77.7 <0.0001
Protein (g/d) 97.8 ± 30.2 92.6 ± 29.6 0.002
Total fat (g/d) 84.5 ± 29.2 86.6 ± 29.8 0.44
SFA (g/d) 29.0 ± 12.0 25.4 ± 10.4 <0.0001
MUFA (g/d) 30.8 ± 11.8 29.6 ± 12.4 0.11
PUFA (g/d) 15.2 ± 6.6 17.1 ± 6.9 0.0002
Values are means ± SD. p < 0.05. *p-values provided by a paired t-test.
MUFA =monounsaturated fatty acids; PUFA = polyunsaturated fatty acids; SFA = saturated fatty acids.
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takes and for changes in PUFA levels in plasma phospho-
lipids (data not shown).
Further analyses revealed that post-supplementation
plasma TG levels were different only for rs2301475
(PLA2G2C) and rs1569480 (PLA2G4A) but not for
rs818571 (PLA2G2F). Figures 1 and 2 show significant
differences between post-supplementation plasma TG
levels of genotype groups for rs2301475 and rs1569480
after adjustments for age, sex, BMI, and energy. How-
ever, the association was no longer significant for these
two SNPs after adjustment for pre-supplementation
plasma TG levels.
Finally, 60 SNPs were included in a linear regression
model, post-supplementation plasma TG levels as the de-
pendant variable, adjusted for pre-supplementation plasma
TG levels, age, sex, BMI, and energy intake. Using the step-
wise bidirectional selection method, SNPs in PLA2G2D,
PLA2G7, and PLA2G4A were associated (p ≤ 0.05) with
post-supplementation TG levels. Rs132989 from PLA2G6,
rs1805018 from PLA2G7, rs679667 and rs12045689 from
PLA2G2D and rs10752979 and rs1160719 from PLA2G4ATable 4 Significant effects of the genotype, the n-3
supplementation and the genotype x supplementation
on TG levels (n = 208)
Genes SNPs Genotype Supplementation Interaction
p p p
PLA2G2C rs2301475 0.0209 <.0001 0.8703
PLA2G2F rs818571 0.0188 <.0001 0.3958
PLA2G7 rs1805018 0.2383 <.0001 0.0286
PLA2G4A rs10752979f 0.9152 <.0001 0.0273
PLA2G4A rs10737277 0.6696 <.0001 0.0241
PLA2G4A rs7540602f 0.1663 <.0001 0.0344
PLA2G4A rs1569480 0.0203 <.0001 0.7758
PLA2G4A rs3820185 0.4778 <.0001 0.0231
*p values are derived from log10-transformed data.
All results were adjusted for age, sex, BMI, and energy intake.
The MIXED procedure (SAS v9.3) was used to test the interaction effects.explained, respectively 1.06, 1.14, 0.98, 0.63, 1.27, and 0.82%
of the trait. In sum, SNPs on those genes explain 5.9% of
the trait.Discussion
In this study, we tested whether the plasma TG levels re-
sponse of healthy overweight adults to n-3 PUFA supple-
mentation is modulated by genes encoding PLA2. Our team
observed that PLA2G2A, PLA2G2C, PLA2G2D, PLA2G2F,
PLA2G4A, and PLA2G6 are modulated by n-3 PUFA sup-
plementation, since they were differentially expressed in
peripheral blood mononuclear cells (PBMCs) after supple-
mentation [13]. PLA2 family was shown to be influenced
by n-3 PUFA supplementation so we included PLA2G7
since its gene product is a secreted enzyme whose activity
is associated with CHD biomarkers [36,37].Figure 1 TG levels after an n-3 PUFA supplementation by genotype
groups for rs2301475 (PLA2G2C).
Figure 2 TG levels after an n-3 PUFA supplementation by genotype
groups for rs1569480 (PLA2G4A).
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fects of the supplementation, genotypes of selected
SNPs in PLA2 genes, and genotype x supplementation
interaction on plasma TG levels. As expected, n-3 PUFA
supplementation significantly lowered plasma TG levels, a
finding that is concordant with results reported in litera-
ture [10,38]. Moreover, three SNPs of PLA2 genes influ-
enced TG levels independently of the supplementation. In
addition, genotypes x supplementation interaction effects
were observed for five SNPs as previously mentioned.
These SNPs and interaction effects considerably contrib-
uted to explain inter-individual variability in plasma TG
levels after n-3 PUFA supplementation. Despite the fact
that some nutrient intakes were significantly different pre-
and post-supplementation, further analyses taking into ac-
count changes in carbohydrate, protein and saturated fat
intakes revealed that results remained the same (data not
shown). SNPs of PLA2G2D, PLA2G7, and PLA2G4A ex-
plained 5.9% of the variance in post TG supplementation,
in a linear regression model.
Our study showed that genetic factors, especially SNPs
of PLA2G2C, PLA2G2F, PLA2G4A, and PLA2G7 influ-
enced plasma TG levels response to n-3 supplementa-
tion and therefore potentially explained the variability
observed which is consistent with findings from other
investigators [9,10,38]. PLA2G2C and PLA2G2F that are
part of the sPLA2 group have been less studied.
PLA2G2C appears to be a non-functional pseudogene,
unlike its rodent counterpart [39]. PLA2G2F has a two-
fold preference for AA over linoleic acid in vitro and
that its expression generally increases in the aorta con-
secutively with advance of atherosclerosis [40,41].PLA2G7 encodes human Lp-PLA2, also known as
platelet-activating factor acetylhydrolase (PAF-AH), which
has been much largely studied in the literature [21]. Lp-
PLA2 may play an important role in the pathophysiology
of inflammation because it participates in the oxidative
modification of LDL [42]. High levels of Lp-PLA2 mass
and activity were associated with the risk of CHD, stroke,
and cardiovascular mortality [43]. It also may be an emer-
ging biomarker for improved cardiovascular risk assess-
ment in clinical practice and a potential therapeutic target
for primary and secondary prevention of CVD [43].
The rs1805017 G and rs1051931 A alleles of PLA2G7
gene were found to be associated with coronary artery
disease (CAD) [44] yet, up to now, studies are inconclusive
on the association between PLA2G7 variants and cardio-
vascular risk [43,45-47]. SNP rs1805018 tended toward
significantly decreased expression of the PLA2G7 gene
[44] and decreased Lp-PLA2 activity [48].
One of our selected SNPs, rs1805018 (I198T), was part
of the SNPs that had a genotype x supplementation
interaction and was in strong-LD with SNPs found in
the literature, namely rs201554087 (V279P), rs1051931
(A379V), and rs1805017 (R92H) [48]. Consequently, we
may suppose that the genotype x supplementation effect
we observed with rs1805018 is partly the reflection of
these other functional SNPs. Further analyses performed
with ESEfinder 3.0 showed that rs1805018 located in the
coding region may impact mRNA splicing. However,
analyses with SIFT and PolyPhen-2 did not confirm the
potential functional effect of this SNP since the amino
acid change was considered tolerated or benign.
Therefore, the majority of genotype x supplementation
effects were observed with SNPs within PLA2G4A gene
(rs10752979, rs10737277, rs7540602, and rs3820185).
PLA2G4A encodes a cPLA2 that is now considered a
central enzyme for mediating eicosanoid production and
thus plays a major role in inflammatory diseases. Indeed,
PLA2G4A hydrolysis of phospholipid substrates has high
substrate specificity for AA at the sn-2 position [21].
The release of AA has been linked to the action of cPLA2
but release of DHA is less clear, although the action of
iPLA2 has been suggested in literature [49,50]. In addition,
a functional variant (rs12746200) was associated with
CVD phenotype mediated by dietary PUFAs [24]. Interest-
ingly, our team demonstrated that participants who did
not lower their TG levels (non-responders) had lower
PLA2G4A expression after n-3 PUFA supplementation
and that PLA2G4A was expressed in opposite direction
between responders and non-responders after supplemen-
tation [13]. We could postulate that a lower PLA2G4A ex-
pression may decrease the release of EPA, DHA, and AA
from cellular membrane and thus decrease activation of
peroxisome proliferator-activated receptors alpha (PPAR-
α) and PPAR-γ and their action to reduce TG levels
Tremblay et al. Lipids in Health and Disease  (2015) 14:12 Page 8 of 9[51-53]. Indeed, n-3 and AA activate PPAR-α to decrease
TG and VLDL secretion and increase fatty acid oxidation
in the liver. N-3 and AA also activate PPAR-γ in the adi-
pose tissues to improve insulin sensitivity, increasing TG
clearance, supressing lipolysis and hepatic TG production,
thus helping to decrease TG levels [54-56].
Conclusions
Data from the present study suggest that SNPs within
PLA2 genes may modulate plasma TG levels after n-3
PUFA supplementation in healthy overweight adults.
These results need to be replicated in other independ-
ent studies, therefore we will be able to better under-
stand the potential functional mechanism underlying
these genetic associations. In conclusion, these results
indicate that gene-diet interaction effects may modulate
the response of plasma TG levels to n-3 PUFA intakes and
thus contribute to the explanation of the inter-individual
variability observed.
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